No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

Real-world analysis reveals that glucagon-like peptide-1 receptor agonists provide cardiovascular benefits for adults with type 2 diabetes. Glucagon-like peptide-1 receptor agonists reduce major ...

Clinical pharmacist and investigator Catherine “Katie” Derington, PharmD, MS, led research that suggests liraglutide, semaglutide, and dulaglutide may be equally safe options for patients with type 2 ...

Rising adoption of automated and AI-enabled synthesis platforms positions pharmaceutical and biotechnology companies for ...

Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection ...

The diabetic drug semaglutide slows chronic kidney disease progression with consistent renal safety in servicemen living with type 2 diabetes. GLP-1 (Glucagon-like Peptide-1) drugs such as liraglutide ...

The most common side effects of GLP-1 medicines are related to digestion: nausea, vomiting, diarrhoea, indigestion, stomach ...

The rise of GLP-1 drugs such as Ozempic and Mounjaro has been nothing short of meteoric. Originally developed to treat ...

Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...

GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...